Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px

Product › Details

LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor)

	Next higher product group	cancer drug
	Status	2014-04-07 development p2 existent
	Organisation	Roche (Group)
	Organisation 2	Oryzon Genomics S.A. (Madrid Stock Exchange: ORY)
	Group	Oryzon Genomics (Group)

Record changed: 2023-07-10

Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x200px

More documents for cancer drug

[1] Ion Beam Applications S.A. (IBA). (9/11/24). "Press Release: IBA’s Joint Venture PanTera Secures EUR 93 Million in Oversubscribed Series A Round to Accelerate Global Actinium-225 Production". Louvain-la-Neuve....
[2] Novartis Pharmaceuticals Corporation (Novartis US). (9/4/24). "Press Release: Novartis Begins Construction of Two New Radioligand Therapy Facilities in the US, Expanding Its World-class RLT Manufacturing and Supply Network". East Hanover, NJ....
[3] NextRNA Therapeutics, Inc.. (8/28/24). "Press Release: Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-coding RNAs (lncRNAs) in Oncology". Berlin & Boston, MA....
[4] Boehringer Ingelheim. (8/27/24). "Press Release: Boehringer Ingelheim to Unveil Groundbreaking oncology Research at WCLC, Demonstrating Strength of Portfolio". Ingelheim....
[5] Coulter Partners. (8/22/24). "Press Release: Coulter Partners Places Industry Veteran Dr. David Hung as Chair of T-Therapeutics"....
[6] Adcendo ApS. (8/20/24). "Press Release: Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor". Copenhagen & Shanghai....
[7] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
[8] AGC Biologics. (8/7/24). "Press Release: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines"....
[9] IDRx, Inc.. (8/7/24). "Press Release: IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)". Plymouth, MA....
[10] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]